Abstract
Gene signatures predictive of chemotherapeutic response have the potential to extend the reach of precision medicine by allowing oncologists to optimize treatment for individuals. Most published predictive signatures are only capable of predicting response for individual drugs, but most chemotherapy regimens utilize combinations of different agents. We propose a unified framework, called the chemogram, that uses predictive signatures to rank the relative predicted sensitivity of different drugs for individual tumors. Using this approach, providers could efficiently screen against many therapeutics to optimize chemotherapy at any time, whether it be for a treatment-naive tumor or a chemo-resistant tumor requiring a new treatment strategy. To demonstrate the utility of the chemogram, we used predictive signatures (extracted from a previously established method) in our framework to rank predicted sensitivity among drugs within cell lines. We then compared the rank order of predicted and observed response against each drug. Across most cancer types, chemogram-generated predictions were more accurate than predictions made by randomly generated gene signatures, signatures extracted from differential expression alone, and was comparable to another established method of drug response prediction. Our framework demonstrates the ability of transcriptomic signatures to not only predict chemotherapeutic response, but also correctly assign rankings of drug sensitivity on an individual basis. Additionally, scaling the chemogram to include more drugs does not compromise accuracy.